## Clinical Context This patient has locally advanced nasopharyngeal carcinoma (Stage III: T4N2M0 or Stage IVA depending on exact T staging) with nodal involvement but no distant metastasis. The goal of management is curative. ## Standard of Care for Locally Advanced NPC **Key Point:** Concurrent chemoradiotherapy (CCRT) with cisplatin is the gold standard for locally advanced nasopharyngeal carcinoma (Stage III–IVA). **High-Yield:** The landmark studies (e.g., RTOG 0615, NCCN guidelines) demonstrate that concurrent cisplatin-based chemotherapy with definitive radiotherapy (70 Gy in conventional fractionation) offers superior locoregional control and overall survival compared to radiotherapy alone or sequential chemotherapy. ## Rationale for CCRT 1. **Radiosensitization:** Cisplatin enhances radiation effect on tumor cells. 2. **Systemic control:** Addresses occult micrometastases, particularly important in NPC due to high propensity for distant spread. 3. **Nodal response:** Improves nodal downstaging and reduces neck dissection rates. ## Management Algorithm ```mermaid flowchart TD A[Biopsy-proven NPC]:::outcome --> B{Stage?}:::decision B -->|Stage I| C[Radiotherapy alone]:::action B -->|Stage II-IVA| D[Concurrent CCRT]:::action B -->|Stage IVB| E[Palliative chemotherapy]:::action D --> F[Cisplatin 100 mg/m² q3w × 3 cycles]:::action F --> G[Concurrent EBRT 70 Gy/35 fr]:::action G --> H[Adjuvant chemotherapy considered]:::action H --> I[Follow-up imaging at 8-12 weeks]:::outcome ``` **Clinical Pearl:** Cisplatin-based CCRT is contraindicated only in patients with severe renal impairment, hearing loss, or neuropathy; carboplatin is a less effective alternative in this setting. **Warning:** Do NOT defer chemotherapy in locally advanced disease — radiotherapy alone yields 5-year OS ~30%; CCRT improves this to ~60–70%. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.